Key result
Fetal brain volume predicts 2-year neurodevelopment in CHD, explaining up to ~45% of variance.
Why the study?
Does fetal brain volume predict 2-year neurodevelopmental outcomes in fetuses with isolated congenital heart disease?
Cohort
Does fetal brain volume predict 2-year neurodevelopmental outcomes in fetuses with isolated congenital heart disease?
p-value: p=<0.05
Small fetal brain volume measured by MRI is a strong independent predictor of 2-year neurodevelopmental outcomes in children with congenital heart disease.
BACKGROUND: Neurodevelopmental impairment is common in children with congenital heart disease (CHD), but postnatal variables explain only 30% of the variance in outcomes. To explore whether the antecedents for neurodevelopmental disabilities might begin in utero, we analyzed whether fetal brain volume predicted subsequent neurodevelopmental outcome in children with CHD. METHODS: Fetuses with isolated CHD and sociodemographically comparable healthy control fetuses underwent fetal brain magnetic resonance imaging and 2-year neurodevelopmental evaluation with the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) and the Adaptive Behavior Assessment System, Third Edition (ABAS-3). Hierarchical regression evaluated potential predictors of Bayley-III and ABAS-3 outcomes in the CHD group, including fetal total brain volume adjusted for gestational age and sex, sociodemographic characteristics, birth measures, and medical history. RESULTS: <0.05), but this was not noted in the control group. Fetal brain volume predicted 10% to 21% of the variance in neurodevelopmental outcome measures in univariate analyses. Multivariable models that also included social class and postnatal factors explained 18% to 45% of the variance in outcome, depending on developmental domain. Moreover, in final multivariable models, fetal brain volume was the most consistent predictor of neurodevelopmental outcome across domains. CONCLUSIONS: Small fetal brain volume is a strong independent predictor of 2-year neurodevelopmental outcomes and may be an important imaging biomarker of future neurodevelopmental risk in CHD. Future studies are needed to support this hypothesis. Our findings support inclusion of fetal brain volume in risk stratification models and as a possible outcome in fetal neuroprotective intervention studies.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in Congenital heart disease. Fetal brain volume vs. Healthy control fetuses was evaluated on 2-year neurodevelopmental outcome (Bayley-III and ABAS-3) (p=<0.05). Fetal brain volume independently predicted 2-year neurodevelopmental outcomes in children with congenital heart disease, explaining 18% to 45% of the variance in multivariable models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: